A compound is provided which comprises at least a portion of an amino acid linker-domain from squalene synthase. In alternative forms, the compound can include the amino-acid linker-domain from various fungus, including S. cerevisiae or the compound can be the functional equivalent and/or mimics an amino acid linker-domain from squalene synthase. A pharmaceutical composition includes the compound and may further include a pharmaceutical carrier. A method is provided for treating or controlling cholesterol metabolism and ergosterol metabolism in non-fungal organisms. One method includes a therapeutic treatment in humans by administering a therapeutically effective amount of the compound or pharmaceutical composition, to a patient in need of treatment, therefrom.

The present specification discloses a transformed Synechococcus elongatus strain which may directly produce squalene from carbon dioxide, and a method for producing squalene and a method for removing carbon dioxide, using the same. In an aspect, the strain may produce squalene using carbon dioxide as a carbon source. The Synechococcus elongatus strain is economically efficient because a high-value added squalene is produced using light and carbon dioxide present in the atmosphere as a carbon source, and the method for producing squalene is eco-friendly because the strain may be utilized to remove or reduce carbon dioxide in the atmosphere by using microorganisms. The strain of the present disclosure may produce only squalene, which is a desired target material with high purity, and has an advantage in that squalene may be continuously mass-produced.

The present invention relates to the control of gene expression by a heterologous glucose-regulated promoter, to microorganisms in which gene expression is controlled by a heterologous glucose-regulated promoter and to methods using said microorganisms for the production of terpenes during glucose-limited fed-batch fermentation.

In an aspect, the disclosure provides methods for making neurotransmitters in a host organism. The neurotransmitters can be cannabinoids and derivatives of cannabinoids. The host cells can be microalgae, fungi or other host cells. In a related aspect, the disclosure provides host cells engineered to have biochemical pathways for making neurotransmitters such as cannabinoids.

The present invention relates to isolated polypeptides that are derived from wildtype Bacillus subtilis S-Adenosylmethionine (SAM) synthase or from a biologically active fragment thereof, wherein said isolated polypeptides comprise an amino acid sequence that, in relation to the amino acid sequence of said wildtype Bacillus subtilis SAM synthase or of the biologically active fragment thereof, comprises at least one amino acid substitution, selected from the group consisting of amino acid substitutions at positions I317 and I105. The present invention further relates to respective isolated nucleic acids, vectors, host cells, uses and methods for the production of SAM derivatives.

The present invention provides compositions and methods of use in investigations of the formation of multiprotein assemblies implicated in disease. Also provided are assays for screening candidate compounds of potential utility in preventing and/or treating such diseases by preventing the assembly of or disrupting the function of multiprotein assemblies.

The invention relates to recombinant microorganisms and methods for producing steviol glycosides and steviol glycoside precursors.

The present invention relates to a genetic construct comprising a nucleic acid sequence encoding cytokinin biosynthetic isopentenyl-transferase enzyme (IPT) operable linked to a promoter allowing expression of said nucleic acid sequence in cambial cells. The invention relates also a method for producing a transgenic plant capable of increased biomass production and/or increased stem volume growth compared to wild type plant and a method for improving the production of biomass and/or increased stem volume growth in trees, as well as to a tree that over expresses an endogenous or exogenous nucleic acid sequence encoding IPT in cambial cells and a wood product obtainable from the transgenic tree.

Aspects of the disclosure relate to biosynthesis of cannabinoids and cannabinoid precursors in recombinant cells and in vitro.

The disclosure relates to biosynthesis of cannabinoids and cannabinoid precursors in recombinant cells and in vitro comprising the use of disclosed prenyltransferase variants.